B. Riley analyst Kalpit Patel raised the firm’s price target on Viridian Therapeutics to $46 from $40 and keeps a Buy rating on the shares. After Viridian presented data from a low dose cohort of VRDN-001, Patel said the results "surprised to the upside with unexpected clinical activity" and argues that potential efficacy superiority to competitor Tepezza is "increasingly likely."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VRDN:
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- ‘The Likelihood of Recession in the Next 6 Months Is Low’: Credit Suisse Suggests 2 Stocks to Buy
- Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease
- Viridian Therapeutics announces first patient enrolled in THRIVE Phase 3 trial
